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Radiotherapy-induced miR-223 prevents relapse of breast
cancer by targeting the EGF pathway
L Fabris1,9, S Berton1,2,9, F Citron1, S D’Andrea1, I Segatto1, MS Nicoloso1,3, S Massarut4, J Armenia1, G Zafarana2, S Rossi3,10, C Ivan3,
T Perin5, JS Vaidya6, M Avanzo7, M Roncadin8, M Schiappacassi1, RG Bristow2, G Calin3, G Baldassarre1 and B Belletti1
In breast cancer (BC) patients, local recurrences often arise in proximity of the surgical scar, suggesting that response to surgery
may have a causative role. Radiotherapy (RT) after lumpectomy signiﬁcantly reduces the risk of recurrence. We investigated the
direct effects of surgery and of RT delivered intraoperatively (IORT), by collecting irradiated and non-irradiated breast tissues from
BC patients, after tumor removal. These breast tissue specimens have been proﬁled for their microRNA (miR) expression, in search
of differentially expressed miR among patients treated or not with IORT. Our results demonstrate that IORT elicits effects that go
beyond the direct killing of residual tumor cells. IORT altered the wound response, inducing the expression of miR-223 in the peri-
tumoral breast tissue. miR-223 downregulated the local expression of epidermal growth factor (EGF), leading to decreased
activation of EGF receptor (EGFR) on target cells and, eventually, dampening a positive EGF–EGFR autocrine/paracrine stimulation
loop induced by the post-surgical wound-healing response. Accordingly, both RT-induced miR-223 and peri-operative inhibition of
EGFR efﬁciently prevented BC cell growth and reduced recurrence formation in mouse models of BC. Our study uncovers unknown
effects of RT delivered on a wounded tissue and prompts to the use of anti-EGFR treatments, in a peri-operative treatment
schedule, aimed to timely treat BC patients and restrain recurrence formation.
Oncogene advance online publication, 15 February 2016; doi:10.1038/onc.2016.23
INTRODUCTION
Wound healing and tumorigenesis are processes that rely on
similar molecular mechanisms,1 including the local production of
growth factors and cytokines that can eventually inﬂuence the
behavior of residual and/or attract dormant or circulating tumor
cells.2 In breast cancer (BC) clinical and experimental evidence
support the notion that the inﬂammatory and wound-healing
responses triggered by the act of surgery may modify the growth
kinetics of micrometastasis, eventually supporting the survival and
the local regrowth of residual BC cells.3–9
Breast-conserving surgery followed by external beam radiation
therapy represents the standard of care for the majority of BC
patients.10 Recent clinical trials have demonstrated that a single
application of radiotherapy delivered intraoperatively (IORT) to the
tumor bed after removal of the tumor mass may be non-inferior to
6 weeks of external beam radiation therapy in preventing the
formation of local recurrences in selected BC patients.11,12
IORT offered the unique opportunity to study the early effects of
radiotherapy (RT) on human tissues in vivo. Our previous study has
demonstrated that IORT is able to modify the post-surgical
microenvironment, by altering the composition of ﬂuids that
normally accumulate in the tumor bed after surgery (drainage
wound ﬂuids, WF).4 Yet, how RT impinges on the molecular
composition of these WF is still unknown.
MicroRNAs (miR) are small, non-coding RNA molecules that
regulate gene expression post-transcriptionally. They are
expressed in a tissue-speciﬁc manner13 and can be secreted and
stably expressed in animal serum/plasma.14 They have emerged as
essential players in the regulation of morphogen and
growth factor bioavailability, through non-cell-autonomous
mechanisms,15 as well as in governing the crosstalk between
tumor cells and their microenvironment.16 Several studies have
shown that ionizing radiations induce changes in miR expression
proﬁles in cells and in preclinical models.17 Yet, the immediate
effects of RT on miR expression and their signiﬁcance in vivo, if
any, are unknown.
Here, we investigate the modulation of miR by RT in human
tissues in vivo. By examining miR expression proﬁles in breast
tissues from IORT-treated BC patients after lumpectomy, we
highlight the importance of the post-surgical tumor–stroma
crosstalk in dictating clinical outcome.
RESULTS
Intraoperative RT induces miR-223 expression in peri-tumoral
breast tissue
We have previously demonstrated that irradiation (IR) of wounded
peri-tumoral breast tissue with IORT changed the molecular
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Figure 1. IORT treatment modiﬁes miR expression in peri-tumoral microenvironment. (a) Schematic representation of the experimental
design. Two specimens of peri-tumoral breast tissue were collected from 29 BC patients undergoing surgery. Among these patients, 12
underwent only surgery and 17 also underwent IORT. From each patient, one specimen was collected right after surgery ('at surgery') and one
30 min post surgery or 30 min post IORT. (b) Heat map of differentially expressed miRs in paired samples of the IORT-treated patients. (c) Venn
diagram of miRs differentially expressed in paired samples of the IORT-treated patients (yellow) and in samples collected post surgery with
respect to post-IORT (blue). miR-223 is differentially expressed in both comparisons (green). (d, e) qRT–PCR of miR-223 expression in the
groups described in a, expressed as normalized for U6 levels (d) or as fold increase in paired samples from each patient. (e) Graphs report
the median value (± s.d.) of samples in each group. Statistical signiﬁcance is reported in each graph and was calculated using the Mann–
Whitney test.
Figure 2. Irradiation induces miR-223 expression both in vivo and in vitro. (a) qRT–PCR of normalized miR-223 expression in samples from mice
treated with IORT, at 2 Gy or 5 Gy, collected at the indicated time point after the irradiation (n= 3). Controlateral non-irradiated (NIR)
mammary gland of each mouse was used as a control (n= 6). (b) qRT–PCR of normalized miR-223 expression in samples from mice subjected
to surgery on the left and surgery plus IORT (5 Gy) on the right mammary gland, after 1 and 2 h from irradiation (n= 4 for each time point).
(c) qRT–PCR of miR-223 (expressed as fold increase over the NIR cells) in MCF-10A mammary epithelial cells (left graph) and in MDA-MB-231
breast cancer cells (right graph) irradiated in vitro with 2 Gy. Data were normalized using U6 expression levels. (d) qRT–PCR of pre-miR-223
expression in paired breast peri-tumoral tissues, described in Figure 1. Specimens were harvested at the moment of surgery, right after tumor
removal (at surgery) or after IORT delivery (post IORT). Data were normalized using GAPDH expression levels. (e) qRT–PCR of pre-miR-223
expression in mouse breast tissues described in b. Data were normalized using GAPDH expression levels. (f) Graph reports normalized
luciferase activity associated with full-length (blue line) and with E2F1-deleted (E2F1-Del) (red line) miR-223 promoter, transfected in MDA-
MB-231. Data are expressed as fold increase over the T0 of irradiation. Schematic representation of the promoters is shown in h. (g) Western
blot analysis of E2F1 expression in MDA-MB-231 cells, irradiated with 2 Gy and collected at the indicated time points after irradiation. Histone
γH2AX and GRB2 expression were used as a marker of IR efﬁcacy and as loading control, respectively. On the right, graphs report
quantiﬁcation of E2F1 (top panel) and γH2AX (bottom panel), expressed as fold increase over the NIR sample. (h) Luciferase activity of full-
length and E2F1-Del miR-223 promoters, transfected in MDA-MB-231 irradiated with 2 Gy expressed as fold induction, with respect to
normalized NIR cells. The Student's t-test or Mann–Whitney test have been used for statistical analysis, as appropriate. Asterisks indicate
signiﬁcant differences, *P⩽0.05; **P⩽ 0.01; ***P⩽ 0.001.
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composition and biological activity of WF drained from BC
patients for 24 h post surgery.4 To get more insights into the
biological modiﬁcations induced by IORT, we collected specimens
from BC patients enrolled in the TARGIT-A trial, undergoing
lumpectomy followed or not by IORT treatment.11,12 We collected
two specimens of normal peri-tumoral mammary tissue from 29
patients (Supplementary Table S1). The ﬁrst specimen was
collected immediately after removal of the primary tumor
(specimen at surgery) and the second one 30 min after surgery
(specimen post surgery) or after IORT treatment (specimen post
IORT; Figure 1a). Pathological scrutiny of breast tissue sampling
was performed to ensure that the mammary gland was
adequately and similarly represented in all specimens
(Supplementary Figure S1). IORT did not induce macroscopic
IORT alters the wound response after breast cancer surgery
L Fabris et al
3
© 2016 Macmillan Publishers Limited Oncogene (2016) 1 – 13
alteration of the mammary gland architecture and composition,
with respect to the samples collected after surgery
(Supplementary Figure S1). From the same patients, we also
collected WF to be used as a surrogate model of wound response
in in vitro experiments.
Given the possible dual action of miR in both cell-autonomous
and non-cell-autonomous manner, we decided to perform a miR
microarray in seven specimens/group of patients, used as
discovery set. Comparative analysis of the two specimens
collected from each patient, at and after surgery, demonstrated
that the act of surgery modiﬁed the expression of 74 miRs
(Supplementary Figure S2A and Supplementary Table S2). The
same analysis performed before and after IORT delivery indicated
signiﬁcant changes in the expression of nine miRs (Figure 1b and
Supplementary Table S3). Forty-one miRs were differentially
expressed between the IORT group versus the group who
received only surgery (Figure 1c, Supplementary Figure S2B and
Supplementary Table S4). Among these, miR-223 was the most
highly and signiﬁcantly modiﬁed (Figure 1b, Supplementary
Figure S2 and Supplementary Tables S2 and S4) and was the
only miR speciﬁcally modulated by IORT (Figure 1c). We validated
this result in a wider collection of specimens (n= 29) by
quantitative reverse transcription–PCR, highlighting that not only
miR-223 expression level was signiﬁcantly augmented in the IORT
group (Figure 1d), but also that it was speciﬁcally increased in
each single patient, comparing the specimen collected at surgery
with that collected 30 min after IORT (Figure 1e).
Thus, miR-223 expression is induced by IR in the mammary
tissue of patients, following surgical removal of BC mass.
RT induces miR-223 expression also in mouse breast tissue in vivo,
and in breast epithelial cells in vitro
In order to test whether modulation of miR-223 was a common
event following breast tissue IR, we set up a mouse model of IORT
treatment, using the Intrabeam device (Carl Zeiss, Oberkochen,
Germany; Supplementary Figure S3). Mice were all subjected to a
surgical procedure and then irradiated in the mammary gland (or
not, in the control group). Mice were then killed 0.5, 1 and 2 h after
IORT (2 or 5 Gy at 5 mm from the applicator) or after surgery alone.
Levels of miR-223 increased in a dose- and time-dependent
manner in IORT-treated mouse breast tissue, peaking at 2 h after
RT (Figures 2a and b). As observed in the tissues from BC patients,
the act of surgery alone did not modify miR-223 expression
(Figure 2b). Similar results were obtained by irradiating in vitro
mammary epithelial cells, such as the MCF-10A and the MDA-
MB-231 cell lines (Figure 2c). MCF-10A, a model of non-malignant
mammary epithelial cells, expressed much higher levels of
miR-223 than MDA-MB-231 basal-like BC cells, both at basal level
and after IR, possibly reﬂecting the tissue source that we observed
in samples from patients (normal peri-tumoral mammary gland).
Thus, miR-223 expression is induced by IR also in mouse
mammary gland in vivo, and in mammary non-malignant and
cancer cells in vitro.
The kinetics of miR-223 expression, observed both in vivo and
in vitro, suggested that IR could induce miR-223 at transcriptional
level. Accordingly, pre-miR-223 expression was upregulated by
IORT, both in specimens from BC patients (Figure 2d) and in
mouse mammary glands (Figure 2e). Moreover, we measured the
activity of miR-223 full-length promoter in irradiated MDA-MB-231
cells and observed that IR induced a time-dependent increase in
luciferase activity (Figure 2f, blue line). It has been recently
reported that the E2F1 transcription factor has a role in controlling
miR-223 expression18,19 and, interestingly, E2F1 protein levels
decreased within 30 min in IR cells (Figure 2g). We thus tested
whether E2F1 could be involved in our context. We measured the
activity of miR-223 full-length promoter and of a mutated
promoter, deleted for E2F1-binding sites, both in basal conditions
and following IR. Although displaying a higher basal activity
(Figure 2h), conceivably for lack of E2F1-mediated suppression,
the deletion mutant was insensitive to IR (Figure 2f, red line),
strongly suggesting that E2F1 represented a critical mediator
of IR-induced transcription of miR-223.
miR-223 directly regulates the expression of epidermal growth
factor
Data collected so far indicated that IR of breast epithelial cells
stimulated miR-223 promoter activity, eventually resulting in the
upregulation of miR-223 expression.
To understand the role of miR-223 in the post-surgery context,
we searched for potential miR-223 targets, coupling proteomics
with bioinformatics analyses. We interrogated six different target-
prediction algorithms for potential miR-223 targets among the
187 cytokines tested in WF in our previous study (Figure 3a).4 By
selecting only miR-223 targets indicated by at least two different
algorithms, we identiﬁed 24 cytokines. Then, we further selected
those cytokines whose expression in WF inversely correlated with
miR-223 levels (nine cytokines) and, ﬁnally, validated their levels in
WF from each patient by ELISA. This approach led to the
identiﬁcation of epidermal growth factor (EGF) and prolactin, as
putative targets of miR-223 that were expressed signiﬁcantly less
in WF from IORT-treated than in WF from untreated patients
(Figures 3b and c and Supplementary Figure S4). We focused our
attention to EGF, which represents a key mediator of BC cell
proliferation in response to surgery.9 We tested its expression also
in a wider panel of WF collected for our previous study.4 Overall,
by analyzing WF from 56 BC patients, we observed that EGF
levels were reduced of about 50% in WF from IORT-treated
patients, with a median expression of 4.71 ng/ml in untreated
patients (n= 27) and of 2.5 ng/ml in IORT-treated patients (n= 29;
P= 0.004, Figure 3b). Thus, EGF is a potential miR-223 target and
its expression levels are reduced in WF from IORT-treated
patients.
We next investigated whether EGF represented a bona ﬁde
target of miR-223 in mammary epithelial cells. EGF is produced as
a long precursor and bioinformatic analyses identiﬁed three
potential miR-223-binding sites in its transcript; one in the coding
region (site 1) and two in the 3ʹ-UTR (site 2 and 3; Figure 3d). Site-
directed mutagenesis of these sequences coupled with luciferase
assays demonstrated that miR-223 expression efﬁciently down-
regulated luciferase activity of EGF-3ʹ-UTR and that binding sites 1
and 3 were necessary to mediate these effects (Figure 3e).
Consistently, overexpression of miR-223 either in MCF-10A or in
different BC cell lines (Figure 3f) reduced EGF expression and
secretion in conditioned media (Figure 3g and Supplementary
Figure S5A). Importantly, conditioned media harvested from
miR-223 overexpressing MDA-MB-453 cells (Supplementary
Figure S5B, left panel) stimulated EGF receptor (EGFR) phosphor-
ylation in BT-474 cells less efﬁciently than conditioned media from
control-transfected cells (Supplementary Figure S5B, right panel).
Similarly, WF from IORT-treated patients less efﬁciently induced
phosphorylation of EGFR in different cellular models, with respect
to WF from control patients (Supplementary Figures S5C and S5D).
It has been proposed that phosphorylation of EGFR at Y1068 is
necessary for the activation of STAT3 and PI3K/mTOR/p70S6K
pathways.20,21 Accordingly, lower phosphorylation of Y1068 EGFR
was coupled with decreased activation of both STAT3 and p70S6K
signaling pathways (Supplementary Figures S5E and F), also in our
context.4
Overall, we demonstrated that EGF is a bona ﬁde miR-223 target
and its reduced expression and secretion in miR-223 over-
expressing cells (or in cells stimulated with IORT-WF) is able to
reduce EGFR signaling pathway activation.
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Figure 3. miR-223 controls EGF expression both in vivo and in vitro. (a) Schematic representation of the approach used to identify potential
miR-223 targets in WF from control and IORT-treated BC patients. (b, c) ELISA quantiﬁcation of EGF (b) and prolactin (c) in WF from patients
subjected to surgery alone (n= 27 for EGF, n= 21 for prolactin) or surgery plus IORT (n= 29 for EGF, n= 21 for prolactin), as indicated. Statistical
signiﬁcance reported in ﬁgure was calculated using the Mann–Whitney unpaired t-test. Two-way ANOVA test conﬁrmed the signiﬁcant
differences in EGF expression among groups (P= 0.006). (d) Schematic representation of putative miR-223-binding sites in EGF mRNA. (e) On
the left side, schematic representation of putative miR-223 seed regions of EGF cloned in their wild-type or mutated form in pGL3 control
vector. Graph on the right reports the normalized luciferase activity of each construct in the presence of miR scrambled (black bar) or miR-223
(green bars), expressed as the ratio between miR-223- and miR-scrambled-transfected cells. Control indicates cells transfected with the empty
pGL3 vector. Asterisks indicate signiﬁcant differences respect to the control. (f) qRT–PCR analyses of basal miR-223 expression (black bars) or
after transduction with miR-223 lentiviral vector (red bars) in MCF-10A and in the indicated tumor-derived cell lines. miR-223 expression was
normalized using U6 levels. (g) ELISA quantiﬁcation of EGF levels in conditioned media harvested from BC cell lines described in f. The
Student's t-test or Mann–Whitney test have been used for statistical analysis, as appropriate. Asterisks indicate signiﬁcant differences, *P⩽ 0.05;
**P⩽ 0.01; ***P⩽ 0.001.
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miR-223 expression hinders WF-induced deregulated growth of
BC cells
Stimulation of BC cells with WF from control patients induced a
rapid and signiﬁcant upregulation of EGF expression (Figure 4a),
suggesting that this could result in cell proliferation. To test
whether miR-223 could impact on this mechanism, we analyzed
the proliferative behavior of normal and tumor-derived mammary
epithelial cells stimulated with WF and stably transduced with
miR-223 (Figure 3f). miR-223 overexpression decreased the
proliferation of both MCF-10A and BC cells (Figure 4b and
Supplementary Figure S6A) and also decreased the anchorage-
independent growth of BC cells (Figure 4c).
Then, we included cells in three-dimensional (3D) matrices, a
condition that more closely resembles the in vivo context.22 In all
tested cell lines, miR-223 overexpression strongly diminished WF-
stimulated 3D growth (Figure 4d). This was particularly evident in
MCF-10A cells, which form well-differentiated structures resem-
bling mammary acini (Supplementary Figure S6B).4,23 In the
presence of WF, MCF-10A displayed a strongly deregulated 3D
growth, with a loss of duct-like morphology and acquisition of
invasive phenotypes (Figure 4e, left panel).4,24 The overexpression
of miR-223 was sufﬁcient to rescue their well-ordered duct-like
morphology (Figure 4e, right panel). Similar results were obtained
using both MCF-7 (estrogen receptor positive (ER+) and proges-
teron receptor positive (PgR+), luminal; Figure 4f and
Supplementary Figure S6B) and BT-474 cells (HER2+, luminal;
Supplementary Figure S6C), indicating that miR-223 ability to
counteract WF-induced cell growth was a general feature
observable in different BC subtypes. Thus, expression of miR-223
is able to counteract the pro-tumorigenic stimuli induced by WF.
miR-223 controls EGF production and cell proliferation in normal
mammary epithelial cells
In contrast with what observed in MCF-10A cells, growth in 3D
matrix of human mammary epithelial cells (HMEC) is not
Figure 4. miR-223 controls growth of breast cancer cells, both in two- and three-dimensional (3D) context. (a) qRT–PCR of EGF expression in
MDA-MB-231 cells, serum starved and then stimulated with wound ﬂuids for the indicated times. Values were normalized using GAPDH
expression and are expressed as fold increase over untreated (T0) cells. (b) Growth curve analysis of MCF-10A cell line stably transduced with
control or miR-223 lentiviral vector, plated on day 0 and then counted every day for 5 days, by Trypan Blue exclusion test. (c) Soft agar assay
quantiﬁcation of BT-474 and MM-453 cells transduced with control or miR-223 lentiviral vector in the presence of 5% WF, allowed to grow for
15 days. (d) Colony number quantiﬁcation of the indicated cell lines, included in 3D matrigel in presence of 5% WF and allowed to grow for
15 days. (e, f) Representative 3D reconstruction of confocal images of MCF-10A (e) or MCF-7 cells (f) transduced with control or miR-223
lentiviral vectors, included in 3D matrix as in d. (e) MCF-10A cells were stained with propidium iodide (PI) to visualize the nuclei (blue). EGFP
expression (green) was used to identify the control or miR-223 transduced cells. (f) MCF-7 cells were stained for E-Cadherin (red) and nuclei
(PI, blue). Data of all graphs represent the mean (± s.d.) of two/three independent experiments performed in duplicates. The Student's t-test or
Mann–Whitney tests have been used for statistical analysis, as appropriate. *P⩽0.01.
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dramatically altered by WF.4 This observation prompted us to
evaluate miR-223 levels in several normal and tumor-derived
mammary epithelial cells. HMEC expressed miR-223 at threefold
higher level than MCF-10A and MCF-12A, two ﬁbroadenoma-
derived cell lines, and up to 20-fold higher than most of other
malignant BC cell lines (Supplementary Figure S7A).
To test the effects of miR-223 downmodulation in normal cells,
we generated stable anti-miR-223 HMEC cells25 (Supplementary
Figure S7B). Downmodulation of miR-223 led to increased EGF
expression and to a moderate but consistent increase in
EGFR-Y1068 phosphorylation (Figures 5a and b). More importantly,
anti-miR-223 HMEC displayed increased growth both in two-
dimensional and 3D contexts, accompanied by increased
Ki67 expression (Figures 5c–e and Supplementary Figures
S7C and S7D) and EGFR phosphorylation (Figure 5f). Consistent
with previous results,4 stimulation with WF did not alter the
Figure 5. Down modulation of miR-223 expression in HMEC increases EGF signaling and promotes deregulated 3D growth. (a) qRT–PCR of
EGF in HMEC control-transfected (black bar) or stably overexpressing anti-miR-223 (red bar). Values were normalized using GAPDH expression
and are expressed as fold increase over the expression level of control cells. (b) Western blot analysis of pY1068 EGFR and total EGFR
expression in lysates from HMEC control or stably overexpressing anti-miR-223, serum starved and then stimulated with WF for the indicated
times. Numbers below represent the quantiﬁcation of pY1068 EGFR, expressed as fold increase over the control at T0. (c) Graph reports
quantiﬁcation of Ki67-positive cells/colony/ﬁeld in control and anti-miR-223 transduced HMEC included in 3D matrix and allowed to grow for
7 days. Four and seven ﬁelds were scored for control and anti-miR-223 transduced HMEC, respectively. Representative images of 3D confocal
reconstruction of HMEC cells are reported in Supplementary Figure 7c. (d) Growth curves of HMEC, control-transfected or stably
overexpressing anti-miR-223, plated on day 0 and then counted every day for 7 days by Trypan Blue exclusion test. Data of all graphs
represent the mean (± s.d.) of two independent experiments, performed in duplicates. (e) Growth in 3D matrigel of HMEC control-transfected
or stably overexpressing anti-miR-223. On the left, representative contrast phase images of the colonies after 7 days of culture are shown.
On the right, graph reports the quantiﬁcation of the colony number in control-transfected and anti-miR-223 overexpressing cells.
(f) Immunoﬂuorescence analysis of pY1068 EGFR (green) in HMEC control or stably overexpressing anti-miR-223 as in e. WGA (red) was used to
label cellular membrane. Graph in the middle shows the quantiﬁcation of the pY1068 EGFR ﬂuorescence intensity, normalized for WGA
expression and reported as arbitrary units (A.U.). Graph on the right reports the quantiﬁcation of the colony area in control and anti-miR-223
overexpressing cells. Each dot represents one colony. The Student's t-test or Mann–Whitney test have been used for statistical analysis, as
appropriate. Asterisks indicate signiﬁcant differences, *P⩽0.05; **P⩽ 0.01; ***P⩽ 0.001.
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morphology of the 3D colony in control HMEC cells, but
abrogation of miR-223 was sufﬁcient to induce a deregulated 3D
growth of the same cells (Figure 5f).
miR-223 expression controls EGFR activation in BC cells
The above data suggested that miR-223 overexpression counter-
acted the wound-induced growth of normal and BC cells, at least
in part, by interfering with an autocrine/paracrine stimulatory loop
involving the EGF–EGFR signaling axis. To verify this hypothesis,
we used different inhibitors of EGFR tyrosine kinase activity. Both
Geﬁtinib and Lapatinib effectively counteracted EGFR phosphor-
ylation following WF stimulation, while Erlotinib was less active
(data not shown). Treatment with Geﬁtinib signiﬁcantly reduced
3D growth of control cells but failed to elicit signiﬁcant effects on
miR-223 overexpressing cells (Figure 6a), corroborating the notion
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that miR-223 impacted on 3D growth essentially via the regulation
of EGF–EGFR pathway. In this setting, Lapatinib (a dual EGFR and
HER2 inhibitor) showed a stronger inhibitory effect than Geﬁtinib,
suggesting that formation of EGFR/HER2 heterodimers could be
involved (Figure 6b).
Overall, these data demonstrate that miR-223 impaired
WF-induced BC cell growth by inhibiting EGF production and,
consequently, EGFR activation. In this context, Lapatinib repre-
sented the most effective inhibitor of WF-induced 3D growth of
BC cells.
EGFR/HER2 inhibition impairs WF-induced activation of STAT3 and
p70S6K signaling pathways
Recently, we demonstrated that robust activation of STAT3 and
p70S6K signaling pathways is crucial for BC cells to mediate the
pro-survival stimuli provided by the post-surgical wound response
and to eventually lead to local recurrence formation.4,8,24,26
Interestingly, following WF stimulation, Lapatinib partially blocked
STAT3 and p70S6K activation, while having only minor effects on
AKT and MAPK signaling, in MDA-MB-231 (Figures 6c and d) and in
a larger panel of BC cell lines of different subtypes (Supplementary
Figures S8A and B). Lapatinib also induced a remarkable increase
in apoptosis, even at suboptimal doses, when miR-223 was
overexpressed in BC cells (Figure 6e). Hence, miR-223 over-
expression signiﬁcantly increased sensitivity to Lapatinib and this
effect was abrogated by the addition of soluble EGF to the culture
medium (Figure 6f). In support of these results, we observed that
even under basal culture condition phosphorylation levels of
STAT3 and p70S6K pathways inversely correlated with miR-223
expression, although more modestly for STAT3 and more robustly
for p70S6K (Supplementary Figure S8C).
Overall, the data collected so far demonstrate that, in the
post-surgical setting, EGF is produced as a consequence of the
wound response and locally promotes activation of EGFR and
downstream pro-survival signaling pathways. The upregulation of
miR-223 following RT interferes with this positive loop, eventually
leading to decreased BC cell survival.
RT interferes with wound-induced BC cell growth
Taken as a whole, our results suggested that RT could prevent
wound-induced BC cell growth not only by killing residual tumor
cells but also by dampening EGF availability in the local
microenvironment. To prove this hypothesis in vivo, we designed
the experiment outlined in Figure 7a. Mice, subjected to breast
surgery (wound cohort) or not (control cohort), were irradiated
(5 Gy) or not (NIR), using an image-guided precision irradiator
(Figure 7a and Supplementary Figure S9A). Only then, all mice
were injected with MDA-MB-231 cells and monitored for tumor
growth. The act of surgery per se signiﬁcantly increased BC cell
growth in vivo (Figure 7b and Supplementary Figure S9B).
Importantly, IR completely abrogated the advantage of wound-
induced tumor growth (Figure 7b, compare “Wound 5 Gy” with
“Wound NIR”, and Supplementary Figure S9B). Conversely, when
delivered to non-wounded breast tissue, IR resulted in only minor
and transient suppression of cancer cell growth (Figure 7b and
Supplementary Figure S9B). Altogether, these data demonstrate
that the post-surgical IR of mammary glands exerts a speciﬁc
effect on wounded tissue and on wound-induced cancer cell
growth.
To verify if these effects were due, at least in part, to miR-223
expression we used the miR-223 knockout (KO) mouse model,
recently characterized by others27 (Supplementary Figure S9C).
Quantitative reverse transcription–PCR conﬁrmed the expression
of miR-223 in the mammary gland of wild-type (WT) and miR-223
heterozygous mice and its absence in miR-223 KO mice
(Supplementary Figure S9D). We observed that levels of EGF,
measured both in serum (103 ± 12 pg/ml in WT versus
149 ± 41 pg/ml in miR-223 KO mice) and in mammary
glands (Supplementary Figure S9D, black line), were slightly
increased in miR-223 KO mice. The higher levels of EGF
observed in miR-223 KO mice resulted in slightly higher
phosphorylation of EGFR in mammary glands of miR-223 KO
mice than in WT littermates (Supplementary Figure S9E),
supporting the possibility that miR-223 regulated the EGF/EGFR
pathway also under physiological conditions.
As described above, we delivered IORT in mouse mammary
gland before cancer cells implantation (Figure 7c and
Supplementary Figure S9F) and then monitored tumor appear-
ance over time. For implantation, we used EO771E2 cells, a very
aggressive syngenic cell line from spontaneous BC of C57BL/6
mouse.28 Absence of miR-223 resulted in signiﬁcant anticipation
of tumor onset (P= 0.024 using a paired t-test; Figure 7d) and
increased tumor volume (Figure 7e). Interestingly, the evaluation
of tumor burden inhibition due to miR-223 expression indicated
that the beneﬁcial effects due to miR-223 induction by IORT
decreased with time (Figure 7e, green line). This ﬁnding further
supports that miR-223 expression, induced in the mammary gland
by IORT, exerts its anti-tumor growth effects by regulating the
immediate wound response.
Peri-surgical treatment with EGFR inhibitors prevents local
recurrence formation
The above data suggested that impairing the activation of EGFR at
the 'right' time could prevent local tumor regrowth after breast
surgery. We thus tested the in vivo efﬁcacy of Lapatinib
administered with a peri-operative treatment schedule, using a
mouse model of BC recurrence.8,26 MDA-MB-231 cells were
injected in mammary fat pad and breast tumor mass allowed to
grow up to ~ 200 mm3. Mice were then randomly divided in four
Figure 6. EGFR inhibitors impair wound-induced breast cancer cell growth. (a) Quantiﬁcation of colony number/ﬁeld of MDA-MB-231 cells,
control-transfected or stably expressing miR-223, included in 3D matrigel in the presence of 5% WF with (blue bars) or without (black bars)
1 μM Geﬁtinib. Data represent the mean (± s.d.) of two experiments performed in duplicates. (b) MDA-MB-231 cells were included in 3D
matrigel in the presence of 5% WF (black bar) plus 1 μM Geﬁtinib (blue bar), or 2.5 μM Lapatinib (red bar), as indicated. Data are expressed as
percent of colonies grown in each condition, with respect to the control (only WF) and represent the mean (± s.d.) of two experiments
performed in duplicates. (c) Western blot analysis of MDA-MB-231 cells stimulated with WF for the indicated times, with or without Lapatinib,
as indicated. The expression of phosphorylated and total forms of EGFR, STAT3, p70S6K, the ribosomal protein S6, ERK and AKT is shown.
Vinculin expression was used as loading control. (d) Quantiﬁcation of pY1068 EGFR, pY705 STAT3, pS240/244 S6 and pT202/Y204 ERK levels in
the indicated BC cell lines, stimulated with WF and treated or not treated with Lapatinib. Data represent the mean of three independent
experiments and are expressed as fold increase of the indicated phospho-proteins, with respect to the T0 untreated condition. (e) Graph
reports apoptotic rate of control (black bars) and miR-223 overexpressing (red bars) SK-BR-3 and MDA-MB-231 cells treated for 24 h with the
indicated doses (μM) of Lapatinib, evaluated as activity of caspase 3/7. Data represent the mean of three independent experiments.
(f) Evaluation of the IC50 of in the indicated control-transfected or miR-223 overexpressing BC cell lines, in the presence or absence of EGF
(5 ng/ml). IC50 values were calculated by nonlinear regression using the GraphPad Prism software (La Jolla, CA, USA). In all graphs, *P⩽0.05;
**P⩽ 0.01; ***P⩽ 0.001; ns, not signiﬁcant; indicates a P⩾ 0.05.
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groups, one sham-treated and the others treated with Lapatinib,
at 3 different doses, for 3 consecutive days (day − 1, day 0 and day
+1, with respect to surgery). Tumors were surgically removed at
day 0 and appearance of local recurrence was monitored over a 7
weeks-long follow-up.
Untreated mice developed local recurrence in 60–70%
of injected sites, in accordance with previous observation.8,26
No relevant difference with control mice was detected when the
lowest dose of Lapatinib was used (Figure 7f). However, treatment
with Lapatinib at doses that efﬁciently inhibited EGFR activation
Figure 7. Peri-surgical inhibition of EGFR prevents local recurrence of breast cancer. (a) Schematic representation of the experiment reported
in b. Before being all injected with MDA-MB-231 cells, mice were randomized in four cohorts; one subjected to breast surgery and no
radiotherapy (wound NIR), one subjected to breast surgery followed by radiotherapy (wound 5 Gy), one subjected only to radiotherapy
(control 5 Gy) and one subjected neither to surgery nor to radiotherapy (control NIR). Tumor appearance and growth was then monitored
over time. (b) Graph reports the volume of orthotopic xenografts, 13 days post injection of MDA-MB-231 cells, in the different cohorts
described in a. Data represent the results from three independent experiments (n= 5+5+6 in each cohort). The Mann–Whitney test has been
used to calculate the signiﬁcance. (c) Schematic representation of the experiment reported in d and e. miR-223+/− and miR-223− /− mice
received IORT (5 Gy) with the Intrabeam device. Then all mice were injected with EO771E2 cells. Tumor appearance and growth was then
monitored for 3 weeks. (d, e) Tumor take rate (d) and growth (e) in miR-223+/− and miR-223− /− mice, treated as described in c. (e) The tumor
burden inhibition due to miR-223 expression (% TBI, green dashed line) is reported. Paired t-test has been used to calculate the signiﬁcance.
(f) Disease-free survival analysis of mice subjected to surgery to remove primary tumors (200–300 mm3) and then left untreated (n= 8, black
line) or treated peri-operatively (3 doses) with Lapatinib at 65 mg/kg (n= 6 yellow line) 100 mg/kg (n= 10 red line) and 150 mg/kg
(n= 10 green line). Data are reported as percentage of mice that did not developed recurrent disease during 7 weeks of post-surgery
follow-up. Kaplan–Meier test has been used to calculate the signiﬁcance. *P= 0.04; **P= 0.005. (g) Representative confocal images
of pY1068 EGFR (green) and nuclei (blue) staining in tumors from mice treated with vehicle or Lapatinib (150 mg/kg) for 3 consecutive days, as
evaluated by immunoﬂuorescence analysis. On the right, graph reports the quantiﬁcation of the mean pY1068 EGFR ﬂuorescence intensity in
control (n= 3) and Lapatinib-treated (n= 4) mice. For each tumor, at least three different ﬁelds were analyzed. Mean± s.d. and signiﬁcance
are shown.
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in vivo resulted in strong reduction of recurrence formation,
rendering nearly 90% of the mice relapse free, when used at
150 mg/kg (n= 10; P= 0.005 in log-rank test; hazards ratio = 9.17;
95% conﬁdence interval 1.562–12.83) and 70% relapse free, when
used at 100 mg/kg (n= 10; P= 0.04 in log-rank test; hazards
ratio = 3; 95% conﬁdence interval 1.043–7.778; Figures 7f and g
and Supplementary Figures S9G and H).
Overall, these data demonstrated that 3 days of peri-surgical
treatment with Lapatinib are sufﬁcient to efﬁciently suppress BC
recurrence.
DISCUSSION
Here, we have investigated the crosstalk existing between residual
BC cells and the post-surgery tumor microenvironment and how
RT may interfere with this crosstalk. Our experiments demonstrate
that application of RT to the tumor bed, immediately after tumor
removal, affects the tissue wound-healing response. A large body
of literature exists on the possible unwanted and harmful effects
of RT. These include onset of cardiac toxicity, appearance of
second tumors and, also, the paradoxical stimulation of tumor cell
growth, via stimulation of hypoxic conditions, tumor neoangio-
genesis and production of pro-metastatic growth factors, such as
transforming growth factor-β.29–33 Whether these harmful effects
are related to the dose, the modality and the timing of RT delivery
is largely unknown. Previous studies have investigated gene
expression changes in BC at differing time points after RT,34,35 but
the protocol of IORT has for the ﬁrst time allowed the investigation
of the early effects of RT in vivo, on a wounded peri-tumoral tissue.
Exploiting this unique possibility, we speciﬁcally chose to focus
on miR modiﬁcations. This was not only due to the peculiar and
pleiotropic nature of miR and to their high relevance in cancer,
but, particularly, for their emerging role as molecules able to act
locally and distantly as 'hormones'.14–16 We have observed that
a group of miR is early modiﬁed by RT, and, among them,
miR-223 increased following RT with very similar kinetics in
humans, mice and cultured mammary epithelial cells, indicating
that the observed effect is speciﬁc and reproducible. Due
to the paucity of material available from patients’ 'normal'
tissue, we could not unambiguously establish which cellular
population (breast epithelial cells, ﬁbroblasts, adipocytes,
stromal cells, tumor inﬁltrating cells...) was the source of
RT-induced miR-223 in vivo. However, our experiments high-
lighted that miR-223 is preferentially expressed in normal
mammary gland than in breast tumors or BC cell lines. This
ﬁnding supports that miR-223 could represent a tumor
suppressor, as recently suggested also by others.36 Accordingly,
our in vitro and in vivo analyses support that, in the context of
wound-induced BC growth, expression of miR-223 has the
potential to suppress tumor growth, at least in part through the
downmodulation of EGF expression and the inhibition of EGF/
EGFR autocrine/paracrine stimulatory loop, initiated by the
wound-healing response. Noteworthy, a signiﬁcant decrease of
local EGF expression after IR in patients with head and neck
cancer37–39 and in mouse bone marrow40 has been observed,
independently supporting our data.
The relevance of EGF/EGFR pathway in cancer progression is
well recognized and extensively investigated.41 Local production
of EGF following breast surgery is also a well-known molecular
event.9 The ﬁnding that IORT, via immediate miR-223 upregula-
tion, negatively inﬂuences this pathway, suggests that designing
new therapies to be administered in the peri-operative setting
may represent a promising strategy to restrain recurrence
in BC patients. Consistently, peri-operative administration of
Lapatinib was sufﬁcient to efﬁciently prevent recurrence formation
in mice.
In conclusion, our work explores a new signaling axis, taking
place in the post-surgery mammary microenviroment that is
therapeutically exploitable to restrain recurrence in BC patients.
Our ﬁndings suggest that proper selection of the 'right' drug for
the 'right' patient will not sufﬁce to obtain the most effective
treatment for each BC patient. The accurate choice of the most
appropriate window of time for drug administration during the




Two peri-tumoral breast tissue samples were collected from 29 BC
patients. For those who underwent only surgery, one specimen
was collected immediately after the surgical excision of the tumor
and a second one 30 min after surgery. For those who underwent
IORT and surgery, IORT was delivered in the tumor bed for 30 min after
tumor removal. From these patients, one specimen was collected
immediately after the surgical excision of the tumor and a second
one 30 min after the end of IORT (1 h from the beginning of IR). Breast
tissue specimens were immediately frozen in liquid nitrogen and stored
at –80 °C. Drainage WF, harvested from patients for 24 h after surgery,
were collected as previously described.4 Unless otherwise speciﬁed,
pools of WFs (430) from patients who underwent only surgery
were used.
Tumor growth in wounded and/or irradiated mice
Athymic nude mice (Harlan, Foxn1nu, females, 6–8 weeks old) were divided
in two cohorts (n= 10 for each cohort): one received surgery and one did
not. After surgery, the area including the second and third mammary gland
was irradiated in half of the mice (n=5) and 3 h after surgery and/or IR, all
mice received an injection of MDA-MB-231 cells in the third mammary
gland. Tumor growth was monitored up to 2 weeks. The animals used in
this experiments were housed in animal facilities accredited by the
Canadian Council on Animal Care and treated in accordance with
approved ethical protocols.
WT, Heterozygous and miR-223 KO C57BL/6 mice (B6.Cg-Ptprca Mir223tm1Fcam/J)
were purchased from The Jackson Laboratory (Sacramento, CA, USA).
Mouse model of IORT
FVB WT female mice were purchased from Charles River Laboratories
(Lecco, Italy). Mice were subjected to surgery followed, or not, by IORT
treatment (Carl Zeiss, Oberkochen, Germany), using the spinal applicator.
Details can be found in Supplementary Materials and Methods.
Xenograft growth in mouse mammary fat pads and treatment
Athymic nude mice (Harlan, Foxn1nu, females, 6–8 weeks old) were
injected with MDA-MB-231 cells. The evaluation of local relapse was
performed as previously described.8,26 Administration of Lapatinib was
performed by oral gavage, following a 3-day 'peri-operative schedule'.
Further experimental details are provided in the Supplementary Materials
and Methods.
Cell culture, transduction, soft agar assay and growth in 3D
matrices
All cell lines were authenticated by BMR Genomics srl, Padova, Italia, on
January 2012, according to Cell ID System (Promega, Madison, WI, USA)
protocol and using Genemapper ID Ver 3.2.1 (Applied Biosystems, Foster City,
CA, USA), to identify DNA STR proﬁles. EO771E2 cell line was a kind gift of Dr
Qiao Li (University of Michigan Medical Center, Ann Arbor, MI, USA). All other
mammary carcinoma cell lines were obtained from ATCC (LGC Standards,
Manassas, VA, USA). All in vitro studies were performed in triplicate, unless
otherwise speciﬁed. A detailed description of all experiments and techniques
is reported in the Supplementary Materials and Methods.
Microarray and molecular biology experiments
Microarray data were submitted using MIAMExpress to the Array-
Express database (accession number: E-MTAB-1562). A detailed descrip-
tion of experiments, including microarray assay and analysis,
protein extraction and western blotting, RNA extraction, quantitative
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reverse transcription–PCR and miR expression is reported in the
Supplementary Materials and Methods.
Statistical analyses
In each experiment, sample sizes were chosen based on statistical power
calculation. The computer software PRISM (version 4, GraphPad, Inc.) was
used to make graphs and all statistical analyses. In all experiments,
differences were considered signiﬁcant when P-value was ⩽ 0.05.
Statistical tests are described in detail in the Supplementary Materials
and Methods.
Study approval
WF and peri-tumoral breast tissues were collected at CRO Aviano, Aviano,
Italy. Scientiﬁc use of biological materials was approved by the Ethic
Committee of CRO Aviano. Speciﬁc informed consent was obtained from
each patient.
All animal experiments were reviewed and approved by the CRO
Institutional Animal Care and Use Committee (OPBA) and conducted
according to that committee’s guidelines.
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